A 52-Week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study Evaluating the Safety of Varenicline Tartrate ( CP-526,555) for Smoking Cessation

Pfizer1 site in 1 country375 target enrollmentOctober 2003

ConditionsSmoking Cessation

Drugsvarenicline (CP-526,555)

Overview

Phase: Phase 3
Intervention: Not specified
Conditions: Smoking Cessation
Sponsor: Pfizer
Enrollment: 375
Locations: 1
Primary Endpoint: Summarization of safety data in smokers treated with either varenicline or placebo.
Status: Completed
Last Updated: 18 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The primary purpose of this study is to obtain safety information on cigarette smokers treated with 52 weeks of varenicline regardless of smoking status.

Registry

clinicaltrials.gov

Start Date

October 2003

End Date

March 2005

Last Updated

18 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Pfizer

Eligibility Criteria

Inclusion Criteria

•Subjects must have smoked an average of at least 10 cigarettes per day during the past year and over the month prior to the screening visit, with no period of abstinence greater than 3 months in the past year.